Organogenesis is led by a passionate team of executives and medical professionals whose core mission is to empower healing through regenerative medicine.
Our leadership team is dedicated to developing and delivering safe, effective, and evidence-based product solutions to clinicians and their patients every day with confidence, expertise, and certainty.
As President and CEO of Organogenesis Inc., Gary S. Gillheeney, Sr. has led the company's growth and development for more than 15 years. When Mr. Gillheeney joined the company as CFO/COO, Organogenesis had just launched its first product, Apligraf® in wound care. Under his guidance, the company has grown, both through organic development as well as acquisitions, into its current position as a leading regenerative medicine company offering a portfolio of products for the advanced wound care and surgical biologics markets. For his work at Organogenesis, Mr. Gillheeney was recognized in 2009 as an Ernst & Young's "Entrepreneur of the Year." He has also served in leadership positions in the biotech and regenerative medicine fields, including his current role on the Massachusetts Biotechnology Council (MassBio) Board of Directors.
Mr. Gillheeney's career in Executive Management, Operations and Finance spans more than 25 years. Prior to joining Organogenesis, he held executive positions at Innovative Clinical Solutions, Ltd. as Chief Operating Officer, Chief Financial Officer, as well as Treasurer and Secretary. Prior to that he held positions as Senior Vice President, Chief Financial Officer, Treasurer, and Assistant Secretary at Providence Energy Corporation. Mr. Gillheeney has a B.S. in Accounting from American International College and an MBA from Bryant College.
Timothy M. Cunningham has served as our Chief Financial Officer since 2016. Prior to joining Organogenesis, Mr. Cunningham was Chief Financial Officer of Vestigo Ventures, a venture capital firm. Previously, from 2014 to 2015, Mr. Cunningham served as Senior Vice President and Chief Financial Officer of DialogTech. From 2011 to 2014, he was Worldwide Vice President, Finance and Operations, of GFI Software SA. Prior to joining GFI, he was Executive Vice President and Chief Financial Officer of Metatomix from 2001 to 2010 and Senior Vice President and Chief Financial Officer of Mediabridge Technologies from 1997 to 2000. Earlier in his career, Mr. Cunningham was in public accounting with KPMG followed by Pricewaterhouse Coopers. Mr. Cunningham earned a B.S. in Accounting from Boston College and an M.B.A. from Boston University. Mr. Cunningham is a certified public accountant.
Brian Grow has served as our Chief Commercial Officer since 2017. Since 2004, he has served in a number of roles at Organogenesis with increasing responsibility, including as our Director of Sales, Commercial Operations, from 2013 to 2016, Associate Director, Marketing, from 2012 to 2013, Project Manager—Apligraf from 2011 to 2013, Regional Sales Manager from 2006 to 2011 and Tissue Regeneration Specialist from 2004 to 2006. Prior to joining Organogenesis, he was a pharmaceutical sales representative for Bristol-Myers Squibb from 2003 to 2004 and a tissue engineering specialist for Innovex/Novartis from 2000 to 2003. Mr. Grow earned a B.A. in Psychology from William Jewell College.
Patrick Bilbo has served as our Chief Operating Officer since 2017. Previously, he served as our Senior Vice President, Regulatory, Government Affairs and Administration and other executive positions from 1999 to 2017. Prior to joining Organogenesis, he was Director, Regulatory and Clinical Affairs, for Cytyc Corporation from 1994 to 1998. Mr. Bilbo earned an M.B.A. from the Boston University Questrom School of Business, an M.A. in Biology and an M.A. in Technology Strategy and Policy from the Boston University Graduate School of Arts & Sciences, and a B.S. degree in Biology from Syracuse University.
Antonio S. Montecalvo has served as our Vice President, Health Policy and Contracting since 2017. Since 2003, he has served in various roles at Organogenesis, including as Director of Customer Support Services from 2003 to 2006. Prior to joining Organogenesis, Mr. Montecalvo served as Director of Accounting for Innovative Clinical Solutions, LTD from 2000 to 2003, as Senior Contracts Specialist for UnitedHealth Group from 1996 to 2000 and as a Senior Accountant for Piccerelli, Gilstein & Company, LLP from 1994 to 1996. Mr. Montecalvo holds a B.S. in Accounting from the University of Rhode Island.
Lori Freedman has served as our General Counsel since 2017. Prior to joining Organogenesis, Ms. Freedman served as Vice President of Corporate Affairs, General Counsel and Secretary of pSivida Corp., a developer of sustained release drug products, since 2006, and held the same positions at Control Delivery Systems from 2001 to 2006. Prior to that, Ms. Freedman served as Vice President, Business Development, and Counsel of Macromedia, Inc., a provider of software for creating Internet content and business applications, from March 2001 through September 2001. Ms. Freedman also served as Vice President, General Counsel, and Secretary of Allaire Corporation, a provider of Internet infrastructure for building business applications, from 1999 until Allaire's acquisition by Macromedia in 2001, as Corporate Counsel of Polaroid Corporation from May 1998 to December 1998 and with the law firm of McDermott, Will & Emery. Mrs. Freedman holds a JD from the Boston University School of Law and a BA in economics and psychology from Brandeis University.
Zorina Pitkin has served as our Senior Vice President, Quality Systems since 2008. Prior to joining the company, Dr. Pitkin served as Acting Head, Regulatory Affairs at Tolerx, Inc. From 2002 to 2007, she was Senior Vice President, Regulatory and Quality for RenaMed Biologics, Inc., and she also served as Vice President, Regulatory and Quality at Circe Biomedical from 1996 to 2002. Dr. Pitkin's range of expertise includes the development of Quality System programs and regulatory strategies for cellular therapies, biologic/device combination products, biologics and xenotransplantation. She holds a Ph.D. in Biological Sciences from the Research Institute of Influenza, Russian Academy of Medical Sciences, and is Regulatory Affairs certified. She has served as a member of the USP Tissue and Tissue-based Products Advisory Panel and as a member of the Regulatory Affairs Professional Society Board of Directors.
Christopher O'Reilly has served as our Vice President, Manufacturing Operations since 2015. Mr. O'Reilly has been with Organogenesis since 1997, starting as a Project Engineer. He has functioned as Director of Process Engineering, East Coast from 2002 to 2015, and as General Manager of West Coast Operations from March 2014 to April 2015. Previously, Mr. O'Reilly served as a Senior Process Engineer for Acambis, Inc., Project Engineer for Genzyme Corporation, Validation Engineer for Kemper-Masterson Inc., and as a Project Engineer for both the Badger Engineers Division of Raytheon, and the Electric Boat Division of General Dynamics. He holds a B.S. in Mechanical Engineering from the University of Massachusetts at Dartmouth.
Thomas L. Pearl has served as our Vice President of Human Resources since February 2018. Prior to joining Organogenesis, Mr. Pearl was Vice President of Human Resources at Siemens AG, Healthcare Sector Laboratory Diagnostics business from 2011 to January 2018, and Vice President of Human Resources for the Diagnostics Division at Siemens AG, Healthcare Sector from 2007 to 2011. Before Siemens, Mr. Pearl worked for Bayer Corporation from 1996 to 2007, in several key management positions for national and international HR operations. Mr. Pearl holds certifications from the Center for Creative Leadership and a Bachelor's Degree in Finance from Siena College.